What Are the ADA Guidelines for Diabetes?
The American Diabetes Association has released updated Diabetes Guidelines in 2022. They mention a few items on the guideline that have a relation to pharmacotherapy which is very important. If you or your loved one has diabetes, then you may need emergency medical care at any time. In that case, in-office pharmacy dispensing can be the best option for you. They not only provide urgent primary care but also you can get medicines while visiting the doctor. For this reason, it has become so popular among people these days.
The Updated Information
Patients suffer from two types of diabetes - type 1 and type 2. Doctors who work with type 2 patients may think that the data on heart failure, cardiovascular and renal outcomes is very beneficial. The guideline has mentioned clearly that first-line therapy relies on patient-centered treatment factors, comorbidities and management needs. The guideline also includes metformin with modification of lifestyle.
It is also true that most doctors or patients still give their first priority to metformin, but the updated guideline also gives an opportunity to the GLP-1 agonist and SGLT2 inhibitor. SGLT2 inhibitors are a type of prescription medicine that patients have to take with diet and exercise who suffer from diabetes type 2. The guideline also has discussed dual antidiabetic therapy in patients who suffer from atherosclerotic cardiovascular disease. The combination of a few agents and the cardiovascular outcomes data are SGLT2 inhibitors and GLP-1 agonists.
The guideline also updated the pharmacotherapy for chronic kidney disease patients. These updates are especially for those patients whose urine albumin is greater than 300 mg/day. They recommend a 30% reduction or greater to slow the CKD progression. The guideline has also mentioned the drug finerenone in this matter. Doctors have to monitor Hyperkalemia as it is a major risk for patients with diabetes type 2.
At a Glance
The guideline has mentioned that doctors must consider metformin therapy to prevent type 2 diabetes in adults who are prediabetic. It is especially true for patients who are between 25–59 years and have higher A1C (e.g., ≥6.0%), a BMI ≥35 kg/m2 and higher fasting plasma glucose (e.g., ≥110 mg/dL).
Book an Appointment
If you want to seek primary care and get medicines while visiting your physician, then contact PD-RX Pharmaceuticals. If you want to know more details about it, give them a call.
**Disclaimer: The information on this page is not intended to be a doctor's advice, nor does it create any form of patient-doctor relationship.